Abstract: Gastric cancer is one of the most common malignant tumors of the digestive tract. Human epidermal growth factor receptor-2 (HER-2) is an important target for clinical treatment of gastric cancer (including gastroesophageal junction adenocarcinoma). Standardized and accurate detection of HER-2 expression in gastroscopic biopsy specimens is vitally important for molecular typing of gastric cancer and selection of anti-HER-2 targeted drug therapy. Preliminary consensuses, based on medical evidence and the internationally accepted Delphi method, have been reached on the clinical significance, applicable population, biopsy operation specifications, specimen pretreatment, detection method, detection quality control, and multidisciplinary cooperation on the HER-2 detection of gastroscopic biopsy specimens. These consensuses will potentially provide guidance for clinical work.